Drug Search Results
More Filters [+]

Anagliptin

Alternative Names: anagliptin, sk-0403, sk0403, sk 0403, cwp-0403, cwp0403, cwp 0403
Latest Update: 2023-11-01
Latest Update Note: PubMed Publication

Product Description

Anagliptin is an orally available, potent, selective inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Anagliptin)

Mechanisms of Action: DPP4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan

Approved Indications: None

Known Adverse Events: None

Company: Sanwa Kagaku Kenkyusho
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Anagliptin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Coronary Artery Disease|Type 2 Diabetes

Phase 3: Type 2 Diabetes

Phase 1: Kidney Diseases|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SSUG

N/A

Unknown status

Type 2 Diabetes

2021-03-30

ACACIA

P4

Completed

Type 2 Diabetes

2020-09-02

REASON

P4

Completed

Coronary Artery Disease

2018-01-01

JapicCTI-132246

P3

Completed

Type 2 Diabetes

2015-09-01

Recent News Events